Cangrelor Tetrasodium

Catalog No.S3737 Batch:S373704

Print

Technical Data

Formula

21Cl2F3N5O12P3S2.4Na
Molecular Weight 864.29 CAS No. 163706-36-3
Solubility (25°C)* In vitro DMSO 100 mg/mL (115.7 mM)
Water 100 mg/mL (115.7 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5% DMSO 95% Corn oil
1.25mg/ml Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Cangrelor (AR-C69931MX) is a potent, competitive P2Y12 receptor inhibitor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation.
Targets
P2Y12 receptor [1]
In vitro Cangrelor is an intravenous ATP analog that directly inhibits, without the need for being metabolized, the P2Y12 receptor in a reversible manner. Cangrelor has a rapid-onset and -offset mechanism of action and achieves significantly greater degrees of platelet inhibition compared with clopidogrel[1].
In vivo Cangrelor is rapidly deactivated by plasmatic ectonucleotidases and, thus, has an extrmely short half-life (2-5 min). Preclinical studies performed in animal models in the early stages of cangrelor development show efficacy in inhibiting thrombus formation and ADP-induced platelet aggregation, as well as a lower increase of bleeding times when compared with IIb/IIIa antagonist[1].

Protocol (from reference)

Selleck's Cangrelor Tetrasodium has been cited by 3 publications

Enhanced metabolic activation of and platelet response to clopidogrel in T cell-deficient mice through induction of Cyp2c and Cyp3a and inhibition of Ces1 [ J Thromb Haemost, 2023, S1538-7836(23)00082-X] PubMed: 36738827
Ginsenosides Rb2 and Rd2 isolated from Panax notoginseng flowers attenuate platelet function through P2Y12-mediated cAMP/PKA and PI3K/Akt/Erk1/2 signaling [ Food Funct, 2021, 10.1039/d1fo00531f] PubMed: 34041517
Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets. [ Sci Rep, 2018, 8(1):9987] PubMed: 29968812

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.